Drug Landscape ›
Epoetin alpha ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 37
Most-reported reactions
Asthenia — 6 reports (16.22%) Platelet Count Decreased — 5 reports (13.51%) Diarrhoea — 4 reports (10.81%) Renal Failure Acute — 4 reports (10.81%) Abdominal Pain — 3 reports (8.11%) Anaemia — 3 reports (8.11%) Confusional State — 3 reports (8.11%) Drug Ineffective — 3 reports (8.11%) Fall — 3 reports (8.11%) Haemoglobin Decreased — 3 reports (8.11%)
Source database →
Epoetin alpha in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Epoetin alpha approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Epoetin alpha in United States?
University Medical Center Groningen is the originator. The local marketing authorisation holder may differ — check the official source linked above.